tcY-NH2 TFA

tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide. tcY-NH2 TFA inhibits thrombin- and AY-NH 2 -induced platelet aggregation and endostatin release, and can be used in the research of inflammation, immunology. In Vitro tcY-NH2 TFA (0-500 μM) inhibits AYPGKF-NH 2 (10 μM)-induced platelet (obtained from male albino Sprague–Dawley rats) aggregation, with an IC 50 value of 95 μM. tcY-NH2 TFA potently activates aorta relaxation (RA) and gastric (LM) contraction, with IC 50 values of 64 μM (RA) and 1 μM (LM). tcY-NH2 TFA (Tc-YPGKF-NH 2 , 400 μM, 5 min) prevents endostatin release and platelet aggregation induced by thrombin or by AY-NH 2. tcY-NH2 TFA (5 μM, 15 min) decreases infarct size (IS) by 51%, and increases recovery of ventricular function by 26% in an isolated heart model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo tcY-NH2 TFA (tail vein injection, 0.6 mg/kg for a single dose) alleviates liver injury in Brain death (BD) rat model, indicated by lower serum ALT/AST levels and better histomorphology. tcY-NH2 TFA (intraperitoneal injection, 0.6 mg/kg for a single dose) increases posttraumatic activation of CD4 + Tregs within the draining lymph nodes in burn injury mice model. tcY-NH2 TFA (intrapleural injection, 40 ng/kg for a single dose) inhibits neutrophil recruitment in experimental inflammation in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Brain death (BD) rat modelDosage: 0.6 mg/kg for a single dose Administration: Tail vein injection for a single dose Result: Reduced blood platelet activation and hepatic platelet accumulation. Attenuated the inflammatory response and apoptosis in the livers. Inhibited the activation of NF-κB and MAPK pathways induced by Brain death (BD). Animal Model: Burn injury model of C57BL/6 N miceDosage: 0.6 mg/kg for a single dose Administration: Intraperitoneal injection Result: Increased expression and phosphorylation of PKC-θ in the presence of platelets, without affecting early posttraumatic hemostasis. Animal Model: BALB/c mice Dosage: 40 ng/kg for a single dose Administration: Intrapleural injection Result: Abolished the number of rolling and adhering neutrophils on the vessel wall. Inhibited CXCL8- and Cg-induced neutrophil migration into the pleural cavity of mice. Form:Solid IC50& Target:PAR4

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet